AbbVie's Phase 2 Study of Upadacitinib (RINVOQ) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
Portfolio Pulse from Benzinga Newsdesk
AbbVie announced positive results from its Phase 2 SLEek study of upadacitinib (RINVOQ) alone and in combination with ABBV-599 in adults with moderately to severely active systemic lupus erythematosus (SLE). The study met primary and key secondary endpoints.
May 31, 2023 | 7:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's upadacitinib (RINVOQ) Phase 2 study met primary and key secondary endpoints in SLE patients, potentially expanding the drug's market.
The positive results from the Phase 2 SLEek study indicate that upadacitinib (RINVOQ) is effective in treating SLE patients. This could potentially lead to an expanded market for the drug, increasing AbbVie's revenues and positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100